Feuerstein Joseph D, Cheifetz Adam S
Division of Gastroenterology, Department of Medicine, Center for Inflammatory Bowel Diseases, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Rabb 425, Boston, MA 02215, USA.
Division of Gastroenterology, Department of Medicine, Center for Inflammatory Bowel Diseases, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Rabb 425, Boston, MA 02215, USA.
Gastroenterol Clin North Am. 2014 Sep;43(3):543-63. doi: 10.1016/j.gtc.2014.05.002. Epub 2014 Jul 5.
Anti-tumor necrosis factor-α (anti-TNF) agents are frequently used in the treatment of inflammatory bowel disease (IBD). Currently, there are 4 anti-TNF therapies that are Food and Drug Administration-approved for moderate to severe IBD: infliximab, adalimumab, golimumab, and certolizumab pegol. For most noninfectious, nonmalignant adverse events, cessation of anti-TNF therapy typically leads to improvement or resolution of drug-induced complications. In this article, the current knowledge regarding the noninfectious and nonmalignant toxicities associated with anti-TNF agents is summarized.
抗肿瘤坏死因子-α（抗TNF）药物常用于治疗炎症性肠病（IBD）。目前，有4种抗TNF疗法已获美国食品药品监督管理局批准用于中重度IBD：英夫利昔单抗、阿达木单抗、戈利木单抗和聚乙二醇化赛妥珠单抗。对于大多数非感染性、非恶性不良事件，停用抗TNF治疗通常会使药物引起的并发症得到改善或缓解。本文总结了目前关于抗TNF药物相关非感染性和非恶性毒性的知识。
